Drug Profile
Research programme: cancer vaccines - Nykode Therapeutics
Latest Information Update: 14 Apr 2022
Price :
$50
*
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
- No development reported B-cell lymphoma; Malignant melanoma; Multiple myeloma; Prostate cancer